Centiva Capital’s BridgeBio Pharma BBIO Stock Holding History

Centiva Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32,300	Closed	-$539K	–	1614
2021 Q4	$539K	Buy	+32,300	New	+$1.37M	0.01%	761

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's BBIO Position: Q3 2025 in Review

Centiva Capital sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 13,680 shares — an estimated $591K sold.

Centiva Capital first reported a position in BBIO in Q4 2019 and held it in 5 quarters. The position peaked at $991K in Q1 2021. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Centiva Capital reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 13,680 BridgeBio Pharma shares in Q3 2025, an estimated $591K.
Centiva Capital first reported a position in BridgeBio Pharma in Q4 2019 and held it in 5 quarters.
Centiva Capital's BridgeBio Pharma position peaked at $991K in Q1 2021.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.